Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

• Status: Terminated
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The purpose of this trial is to investigate if there is any change in the mechanism of energy expenditure (i.e. the way in which energy is used) in patients with type 1 diabetes, whilst taking two different, commercially available insulins for the treatment of their diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin Detemir; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting; Isophane insulin, beef; Isophane Insulin, Human

Criteria

Inclusion Criteria:

• Type 1 diabetes for more than 12 months

• Current treatment: Basal-bolus insulin regimen for more than three months (i.e. at least one daily injection of long-acting insulin (including insulin glargine) and fast-acting insulin with each main meal)

• HbA1c (glycosylated haemoglobin A1c) between 7.0 and 11.0%

• Able and willing to maintain consistent physical activity level throughout the entire study period

• Able and willing to maintain consistent eating habits throughout the entire study period

Exclusion Criteria:

• Proliferative retinopathy that has required acute treatment within the last six months

• Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the Investigator

• Liver, kidney or heart problems as judged by the Investigator

• Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures

• Known or suspected allergy to trial products or related products

• Receipt of any investigational drug within one month prior to this trial